The Mesothelioma Center at Asbestos.com proudly welcomes Dr. Catherine Perrault, D.O., a seasoned family physician and U.S. Navy veteran, to its Patient Advocate team. Dr. Perrault brings her ...

Prasad Adusumilli and colleagues have shown that CAR T cells that start to lose power can be revived by immunotherapy drugs given several weeks later. Mesothelioma is a rare cancer that affects the ...

WASHINGTON – People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the ...

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received ...

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

A new research perspective was published in Oncoscience (Volume 11) on May 23, 2024, entitled, "Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant ...

Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...